Budget Amount *help |
¥17,550,000 (Direct Cost: ¥13,500,000、Indirect Cost: ¥4,050,000)
Fiscal Year 2011: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2010: ¥5,460,000 (Direct Cost: ¥4,200,000、Indirect Cost: ¥1,260,000)
Fiscal Year 2009: ¥6,630,000 (Direct Cost: ¥5,100,000、Indirect Cost: ¥1,530,000)
|
Research Abstract |
While multimodal treatments have been performed for the treatment of head and neck cancers, the prognoses of the patients with advanced head and neck cancer are still poor. The estimated survival rates of those patients are around 30%. New strategies for the treatment for head and neck cancer are desirable. To address this issue, we developed the midkine promoter-driven replication-selective adenoviral vector containing siRNA for EGFR or VEGF. With this adenoviral vector, synergistic effect of oncolytic adenovirus and inhibition of oncogene via RNA interference is effect.
|